How many people relapse after finishing a course of TMS?

In the largest durability study on record, close to 30 percent of people who reached full remission after a course of TMS relapsed within the following year, while roughly 70 percent stayed well through the full 12 months. That data comes from a multisite, naturalistic follow up of 257 patients published in the Journal of Clinical Psychiatry, one of the few studies that tracked people for a full year after their acute TMS course ended rather than stopping at the more common 3 or 6 month mark.

A separate 6 month, multisite study of 99 patients who had responded to TMS, published in Brain Stimulation, found a comparable pattern using a different lens. About 10 percent met full criteria for relapse within six months. A larger share, just over a third, showed some symptom worsening that fell short of full relapse, and among that group, the large majority regained their benefit after a handful of additional TMS sessions. That detail matters because it is one of the earliest data points showing that retreatment, not just the original course, is part of how durability plays out for a meaningful number of patients.

These figures describe what happened to people TMS had already helped. Whether TMS works in the first place is a different question with its own body of research. This is specifically about what happens to the benefit once the daily sessions stop, which is a less commonly reported number and the one that matters most for anyone approaching their last appointment.

Is there a specific time window when relapse risk is highest?

Yes. Across multiple studies, the first six months after the last TMS session is consistently the highest risk window, with more than one analysis pointing to around the five month mark as a peak.

In the 12 month follow up study of TMS remitters described above, symptom reemergence was heavily front loaded, with most cases occurring in the first six months rather than spreading evenly across the year. A 2023 systematic review of maintenance TMS protocols, published in the Journal of Personalized Medicine, identified the five month mark after acute treatment as the point where relapse risk climbs most sharply, which is part of why several maintenance TMS schedules are built to run at least that long before tapering further.

This timing has a practical implication that is easy to miss. A person can feel genuinely stable at the one month mark after finishing TMS, reasonably stop thinking of themselves as a patient, and then find the ground shifting three, four, or five months later, right around the point when the acute course is furthest from memory and any post treatment check ins have often already stopped. The risk window does not announce itself in advance.

None of this means relapse is inevitable during those months, and most people who respond to TMS do not relapse at all. It means the window is identifiable well enough to plan around, which is useful information for deciding how long to stay connected to some form of support after the last session, rather than treating the final appointment as the end of the process.

What is maintenance TMS, and does it actually work?

Maintenance TMS is a schedule of periodic TMS sessions after the acute course ends, spaced out over weeks or months, used specifically to hold onto an existing benefit rather than to treat a new episode. It is a real, studied practice with controlled trial evidence behind it, though researchers have not settled on one standard protocol.

A propensity adjusted study in the Journal of Affective Disorders followed 59 patients who had responded to an acute TMS course. Those given 20 weeks of tapering maintenance sessions relapsed at a rate of 37.8 percent, compared with 81.8 percent among patients who received no further TMS, a gap that held up after adjusting for other differences between the groups. A larger randomized trial of 281 patients, published in Translational Psychiatry, compared a full year of clustered maintenance TMS sessions against antidepressant medication alone and found relapse or recurrence in just 15.9 percent of the group that combined maintenance TMS with medication, versus 44.4 percent on medication alone.

The 2023 systematic review referenced above reviewed the maintenance TMS evidence base as a whole and found it still limited, made up mostly of open label studies, case reports, and a small number of randomized trials, with no shared consensus on the ideal schedule. One finding did recur across studies: protocols offering two or fewer sessions a month did not meaningfully protect against relapse, while more frequent early schedules that gradually tapered performed better.

The fair summary is that maintenance TMS is grounded in real, peer reviewed trials rather than marketing claims, and the results so far are encouraging. It is also still an evolving practice, not a fully standardized one, and anyone considering it should expect their provider to be working from a developing body of evidence rather than a single fixed protocol.

Does adding therapy or medication management change how long TMS benefits last?

The best controlled evidence available points to yes. In the same Translational Psychiatry trial described above, patients who combined maintenance TMS with antidepressant medication relapsed at 15.9 percent over 12 months, compared with 24.2 percent on maintenance TMS alone and 44.4 percent on medication alone, meaning the combination outperformed either approach used on its own.

It is also worth noticing how the underlying durability research is built in the first place. Continued psychiatric care is not an afterthought in these studies, it is part of the design. The 6 month Brain Stimulation study used protocol specified continuation antidepressant medication as part of its methodology, and the 12 month Journal of Clinical Psychiatry follow up tracked patients who remained in ordinary psychiatric care, including medication management for most of them, throughout the follow up year. The published durability numbers for TMS mostly describe people who kept seeing a prescriber or therapist afterward, not people who left their last session with no other support in place.

What the literature has not isolated, at least not in a study specific enough to cite as a verified primary source here, is a precise figure for how much psychotherapy alone, separate from medication, adds to TMS durability. That is a real gap. What is well established, from a different corner of behavioral health research, is the broader principle that structured continuing contact after an intensive treatment episode is associated with more consistent outcomes than stopping all support at once. The National Institute on Alcohol Abuse and Alcoholism has reviewed this exact pattern in substance use recovery and found that continuing care of longer duration, with active effort to stay engaged with the person, produces more consistently positive results, and that people at higher relapse risk tend to benefit the most from it.

Applied to TMS, the pattern lines up even though the two research areas are not identical. A finished course of TMS is, in its own way, an intensive treatment episode. What happens structurally in the weeks after it ends appears to matter, even though the specific contribution of talk therapy alone has not yet been isolated in a dedicated TMS trial.

Why would a treatment that changes brain activity still need behavioral support afterward?

Because TMS changes patterns of brain activity, not the daily habits, relationships, and routines that depression had already reshaped while it was active. Imaging research on patients who respond to TMS has found measurable changes in functional connectivity between brain regions involved in mood regulation, including the prefrontal cortex and structures like the amygdala, according to a review of connectivity findings after rTMS treatment. A change like that is real, and it is not the same thing as a rebuilt sleep schedule, a repaired relationship, or a return to work that actually feels sustainable.

This is not a criticism of TMS. TMS is FDA cleared, the acute course has genuine evidence behind it, and nothing here argues otherwise. The point is narrower than that. A course of TMS is a medical intervention delivered over a period of weeks. Depression, for most people who reach the point of trying TMS, is also a set of learned patterns, isolation, avoidance, disrupted routine, strained relationships, that built up over months or years before treatment started. Shifting the brain's activity pattern can lift the floor those patterns rest on. It does not automatically rewrite the patterns themselves, and nothing in the research suggests it should be expected to.

A similar structural gap is well documented in other parts of behavioral health. Someone can complete a residential treatment program in genuinely good condition and still face a meaningfully higher risk of setback if they leave with no plan for the weeks that follow, which is a large part of why continuing care exists as its own field of study in addiction treatment. Finishing a TMS course is a different kind of treatment, but a similar kind of transition. The neurological work is done. Translating a changed baseline into a changed daily routine is a separate piece of work, and it does not happen automatically just because the sessions are over.

What conditions is TMS actually FDA cleared to treat?

TMS is FDA cleared for four indications: major depressive disorder since 2008, obsessive compulsive disorder since 2018, smoking cessation since 2020, and anxious depression, meaning anxiety symptoms in people already being treated for major depressive disorder, since 2021. It is not FDA cleared for alcohol use disorder or opioid use disorder.

The original clearance, granted to the NeuroStar system in 2008, covered adults with major depressive disorder who had not improved on at least one prior antidepressant. The FDA cleared a device for OCD in August 2018 through its De Novo pathway, the regulatory route used when a device is novel enough that no earlier cleared device is a direct match, based on a randomized, multicenter trial of 100 patients. That clearance was the first time any noninvasive device had been cleared specifically for OCD. Smoking cessation clearance followed in August 2020, the first FDA clearance of a TMS device for any addiction related indication, and clearance for anxious depression, covering people with major depressive disorder whose depression comes with significant anxiety, followed in August 2021. Each expansion required its own clinical evidence submitted to the FDA, which is why the four indications arrived years apart rather than all at once.

Alcohol use disorder and opioid use disorder are active areas of TMS research, with early trials reporting reduced cravings and other encouraging signals, but neither has reached FDA clearance as of this writing. Anyone considering TMS specifically for a substance use disorder, rather than for depression that happens to coexist with one, should know that distinction before starting treatment.

Epic Journey Recovery does not administer TMS and is not a treatment facility. The team coordinates TMS and ketamine therapy through contracted, licensed providers in Orange County as one part of a broader plan, which is a different role from prescribing or delivering the treatment directly.

What does support after a TMS course actually look like?

In practice, it looks like someone helping translate a changed baseline into a changed routine, sleep, movement, work, and relationships, the pieces of daily life a course of TMS does not touch directly. Epic Journey Recovery is concierge recovery coaching based in Newport Beach, California, working in person across Orange County and virtually nationwide, built around exactly this kind of period after an intensive treatment episode ends.

Engagement typically starts with a 90 day core period, when a full team, coaches, holistic practitioners, functional medicine, a neurologist, a psychiatrist, and licensed therapists, works intensively with a person to rebuild structure around whatever changed during treatment. That upfront period is where the habits, routines, and relationships that depression had worn down actually get rebuilt, in coordination with whatever medical treatment, including TMS, a person already has in place. Most people stay engaged for up to about six months, and many then taper down to roughly one session a week with whoever on the team they connected with most. Epic Journey is not a treatment facility, has no beds, is cash pay, does not bill insurance, and does not prescribe or administer TMS itself.

To be clear about what the research does and does not support here: there is no study showing that any particular coaching or aftercare model changes TMS outcomes specifically, and nothing in this piece claims otherwise. What the durability and continuing care research does show is that structured support in the months after an intensive treatment episode is associated with more consistent outcomes than stopping all support the moment treatment ends. That is the gap this kind of work is built to sit inside, translating a medical intervention into a daily life that holds up, not a promise about what the treatment itself will do.

Anyone finishing a TMS course, or weighing whether to start one, who wants to think through what the months afterward should actually look like can start with a free consult.

Questions people ask

Does the benefit from TMS wear off over time?

For a meaningful share of people who respond, some benefit can fade after the acute course ends. Multisite follow up studies have found that among people who reach full remission, close to 30 percent relapse within a year, with most of that happening in the first six months. That said, most remitters do stay well, and relapse, while documented, is not the most common outcome.

How soon could depression symptoms come back after TMS ends?

The highest risk window identified in the research is the first six months after the acute course, with some analyses pointing to around month five as a peak. Symptom reemergence in published studies has been front loaded toward this period rather than spread evenly across the following year, which is one reason maintenance schedules are often built to run at least that long.

Is TMS FDA cleared for anxiety or substance use disorders?

TMS is FDA cleared to reduce anxiety symptoms specifically in people already being treated for major depressive disorder, a presentation known as anxious depression, cleared in 2021. It is not FDA cleared as a standalone anxiety disorder treatment, and it is not FDA cleared for alcohol use disorder or opioid use disorder, both of which remain active research areas rather than approved indications.

Does Epic Journey Recovery provide TMS?

No. Epic Journey Recovery is concierge recovery coaching, not a treatment facility, and it does not administer or prescribe TMS. The team coordinates TMS and ketamine therapy through contracted, licensed providers in Orange County as part of a person's broader plan, working in person across Orange County and virtually nationwide.

What does Epic Journey Recovery do after a TMS course ends?

The team helps build the daily structure, routine, and follow through that translate a medical treatment into a different day to day life. Engagement typically starts with an intensive 90 day core period with the full team, and most people stay engaged for up to about six months before many taper to roughly weekly sessions.

Sources